Financial risk is always associated with drug discovery. But the benefit that a blockbuster drug can bring to the business can be phenomenal if you can take that risk. — Pankaj Patel Copy Share Image
Cadila, India's sixth-largest drugmaker by sales, spent $250 million developing Lipaglyn, a new chemical entity or new discovery, and aims to spend another $150 million to $200 million to launch the drug outside India. — Pankaj Patel Copy Share Image
Thinking of possibilities is like driving a car on a freeway. You have an open road that stretches endlessly before you where your thoughts… — Pankaj Patel Copy Share Image
Financial risk is always associated with drug discovery. But the benefit that a blockbuster drug can bring to the business can be phenomenal if… — Pankaj Patel Copy Share Image
The first award that I recall having received was in the form of a scholarship when I was studying in the 5th standard. I… — Pankaj Patel Copy Share Image
During an economic slowdown, one needs to be cautious, but I think it's equally important to not get sucked into the vortex of defensive… — Pankaj Patel Copy Share Image
It's the sum of the parts that make up the whole, so in my opinion excellence comes from how one undertakes to do something.… — Pankaj Patel Copy Share Image
One of the big myths about philanthropy is that it's all about donating funds for a cause. I like to look at it quite… — Pankaj Patel Copy Share Image
Cadila, India's sixth-largest drugmaker by sales, spent $250 million developing Lipaglyn, a new chemical entity or new discovery, and aims to spend another $150… — Pankaj Patel Copy Share Image
